Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus LIBRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus LIBRIUM.
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE vs LIBRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
Binds to benzodiazepine site on GABA-A receptor, potentiating GABAergic inhibition and increasing chloride ion conductance.
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
5-25 mg orally 3-4 times daily; or 50-100 mg intramuscularly or intravenously initially, then 25-50 mg 3-4 times daily as needed.
None Documented
None Documented
Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment.
Terminal elimination half-life of chlordiazepoxide is 24-48 hours; active metabolite desmethyldiazepam has half-life of 36-200 hours; with repeated dosing, effective half-life extends due to accumulation of active metabolites.
Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates of chlordiazepoxide and demoxepam, <2% unchanged); approximately 60-70% of a dose appears in urine as metabolites, with 4-9% in feces via biliary elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine